Edition:
United States

Acorda Therapeutics Inc (ACOR.OQ)

ACOR.OQ on NASDAQ Stock Exchange Global Select Market

19.78USD
16 Nov 2018
Change (% chg)

$0.81 (+4.27%)
Prev Close
$18.97
Open
$18.86
Day's High
$19.86
Day's Low
$18.68
Volume
183,904
Avg. Vol
228,081
52-wk High
$36.25
52-wk Low
$15.65

Chart for

About

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra... (more)

Overall

Beta: 1.45
Market Cap(Mil.): $917.88
Shares Outstanding(Mil.): 47.56
Dividend: --
Yield (%): --

Financials

  ACOR.OQ Industry Sector
P/E (TTM): -- 79.36 29.34
EPS (TTM): -2.91 -- --
ROI: -11.10 -0.30 13.58
ROE: -20.93 -2.98 15.11

U.S. appeals court invalidates Acorda patents on MS drug

A U.S. appeals court on Monday invalidated Acorda Therapeutics Inc patents covering its multiple sclerosis drug Ampyra, opening the door to generic competition for the company's flagship product.

Sep 10 2018

UPDATE 1-U.S. appeals court invalidates Acorda patents on MS drug

Sept 10 A U.S. appeals court on Monday invalidated Acorda Therapeutics Inc patents covering its multiple sclerosis drug Ampyra, opening the door to generic competition for the company's flagship product.

Sep 10 2018

UPDATE 2-Acorda loses bid for U.S. court order halting generic Ampyra sales

July 25 A U.S. appeals court on Wednesday denied a request by Acorda Therapeutics Inc for a temporary court order blocking generic drug companies from launching lower-cost versions of its multiple sclerosis drug Ampyra.

Jul 25 2018

Acorda loses bid for U.S. court order halting generic Ampyra sales

A U.S. appeals court on Wednesday denied a request by Acorda Therapeutics Inc for a temporary court order blocking generic drug companies from launching lower-cost versions of its multiple sclerosis drug Ampyra.

Jul 25 2018

Drugmakers oppose Acorda's bid to block generic MS drug's release

Three generic drug manufacturers are urging a federal appeals court to reject Acorda Therapeutics Inc's "extraordinary" request for an order blocking them from launching a generic version of multiple sclerosis drug Ampyra before the case is decided.

May 31 2018

Earnings vs. Estimates